ZEISS INTRABEAM 600

Melding two worlds into one benefit.

Local precision

Time
 matters

Proven performance

Local precision

The X-ray source (XRS) with different applicator types creates a very focused radiation field. This leads to a targeted local high dose irradiation and enables increased tumor bed sterilization.1 A very low radiation scattering spares healthy structures and organs at risk from radiation reducing unwanted side-effects2 in contrary to conventional treatment workflows.

Precision and immediacy - one step ahead with IORT during tumor resection

Treatment versatility with our different types of INTRABEAM® Applicators from ZEISS

ZEISS INTRABEAM Spherical Applicator

The ZEISS INTRABEAM Spherical Applicator can be used for the intracavitary intraoperative delivery of radiation to the tumor bed, e.g. at the time of breast conserving surgery.

ZEISS INTRABEAM Needle Applicator

The ZEISS INTRABEAM Needle Applicator can be used for the interstitial irradiation of tumors, e.g. in the treatment of vertebral metastases or brain tumors.

ZEISS INTRABEAM Flat Applicator

The ZEISS INTRABEAM Flat Applicator can be used for the treatment of the tumor bed on surgically exposed surfaces, e.g. tumors of the gastrointestinal tract.

ZEISS INTRABEAM Surface Applicator

The ZEISS INTRABEAM Surface Applicator can be used in the treatment of the tumor bed on the surface of the body, for example, irradiation of non-melanoma skin cancers.

Time matters

Immediate irradiation during surgery in the OR prevents tumor reformation stimulated by wound healing after resection3,4 and can lead to shorter overall treatments. This efficiently saves hospital time without compromising outcomes and lets patients benefit from a completed treatment while sleeping.5

Shorter overall treatments

Post-operative treatment times of up to 6.5 weeks can be reduced to 3-5 weeks or even be eliminated for selected patients when adding IORT during breast-conserving surgery (BCS).2

Proven performance

ZEISS INTRABEAM devices have an extensive record of +250 peer-reviewed publications and +20 studies from over 30 countries confirming the clinical value of personalized and patient-centric IORT treatment options. This helps you to meet future clinical demands and secure reimbursements – a primary aspect of successful healthcare management in the future.

Learn more about study and treatment activities of your peers worldwide

Interact with map locations to discover details

Morgantown, USA | Brain Metastases

Cifarelli, C., et al.

West Virginia University Hospital

Intraoperative radiotherapy (IORT) for surgically resected brain metastases: outcome analysis of an international cooperative study

Evidence: Level 2
No. of patients: 54
Median follow-up: 7.2 months
No. of centers: 3

Reference: Cifarelli, C.P., et al. (2019). Intraoperative radiotherapy (IORT) for surgically resected brain metastases: outcome analysis of an international cooperative study. J Neurooncol 145, 391 397. https://doi:10.1007/s11060-019-03309-6

Also in Morgantown - Vargo, J.A., et al. (2018) investigating the feasibility of dose escalation for IORT vs. SRS during brain metastases resection.

Cleveland, USA | Brain Metastases

Weil, R.J., et al.

Cleveland Clinic

Intraoperative radiotherapy to treat newly diagnosed solitary brain metastasis: initial experience and long-term outcomes

Clinical outcomes for IORT with INTRABEAM® to the cavity during brain metastasis resection show comparable results for local and distant control and long-term survival compared to conventional teatment modalities.

Evidence: Level 2
No. of patients: 23
Median follow-up: 22.0 months
No. of centers: 1

Reference: Weil, R. J., et al. (2015). Intraoperative radiotherapy to treat newly diagnosed solitary brain metastasis: initial experience and long-term outcomes, Journal of Neurosurgery JNS, 122(4), 825-832

Nantes, France | Breast Cancer

Le Blanc, M., et al.

Institut De Cancérologie De L'Ouest - Nantes

Medico Economic Study, Randomized, Comparing Intraoperative Radiotherapy With Intrabeam® on Surgical Resection Bed Versus Conventional Surgery + EBRT in Postmenopausal Patients Operated by Conservative Surgery for Low Risk Breast Cancer

Scope: Comparison of IORT with INTRABEAM® versus EBRT, in terms of costs, local-regional survival without recurrence, rate of early and late complications, impact aesthetic outcome and quality of life of patients.

Evidence: Level 1
No. of patients: 246
No. of centers: 9

Reference: Clinical Trial Identifier: NCT03637738

Guangdong, China | Breast Cancer

Ning, L., et al.

Guangdong Academy of Medical Sciences

Intra-operative Radiotherapy After Breast-conserving Surgery in Treating Women With Ductal Carcinoma in Situ Breast Cancer

Scope: Effectiveness measurement of intraoperatve radiotherapy (IORT) during breast-conserving surgery for low grade ductal carcinoma in situ breast cancer.

Evidence: Level 1
No. of patients: 222
No. of centers: 1

Reference: Clinical Trial Identifier: NCT02389673

London, UK | Breast Cancer

Vaidya, J., et al.

University College London

Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial

Clinical outcomes of single-dose IORT delivered during breast-conserving surgery show significantly fewer non-breast-cancer deaths compared to EBRT.

Evidence: Level 1
No. of patients: 3451
Median follow-up: 29.0 months
No. of centers: 33

Reference: Vaidya, J. S., et al. (2014). Risk-adapted targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. The Lancet, 383(9917), 603–613.

Also active in London - Vaidya, J., et al., with TARGIT-B comparing IORT Boost with EBRT Boost in early-stage breast cancer, 1790 patients in 35 centers planned (Clinical Trial Identifier: NCT01792726)

Mannheim, Germany | Glioblastoma multiforme (Brain)

Giordano, F., et al.

University Medical Center Mannheim

A Multicenter Randomized Phase III Trial on INTraoperative RAdiotherapy in Newly Diagnosed GliOblastoma Multiforme (INTRAGO II)

Evidence: Level 1
No. of patients: 314 planned
No. of centers: 20 planned

Reference: Clinical Trial Identifier: NCT02685605

Other Level 1 & 2 studies in Mannheim - INTRAGO I (Brain), a pooled analysis (Brain), TARGIT-E (Breast) and Kypho-IORT (Spine)

Seoul, South Korea | Pancreatic Cancer

Lee, I.J., et al.

Gangnam Severance Hospital

A Prospective, Phase II Study Investigating Efficacy of Intraoperative Radiation Therapy for Resectable Pancreatic Cancer

Scope: Investigation of IORT efficacy resectable pancreatic adenocarcinoma patients with regards to local recurrence rate after surgical resection with and without IORT.

Evidence: Level 2
No. of patients: 42 planned
No. of centers: 1

Reference: Clinical Trial Identifier: NCT03273374

Changchun, China | Rectal Cancer

Wang, M., et al.

Second Hospital of Jilin University

Single Center Study of Intraoperative Radiotherapy for Middle and Low Rectal Cancer in the Standard of Peritoneal Inversion Rectal Cancer

Scope: Assessment of post-op acute complication and short-term acute efficacy for patients with middle and low rectal cancer treated with IORT after intersphincteric resection.

Evidence: Level 1
No. of patients: 50
No. of centers: 1

Reference: Clinical Trial Identifier: NCT03209336

Chicago, USA | Recurrent Brain Tumors

Kalapurakal, J.A., et al.

Northwestern Memorial Hospital

Final Results of a Phase I Dose Escalation Study of Intraoperative Radiation Therapy in Children with Radiation Recurrent Posterior Fossa Tumors

Clinical outcomes of IORT after maximal tumor resection showed no irreversible grade 3 or higher toxicity in patients.

Evidence: Level 2
No. of patients: 11
Median follow-up: 33.0 months
No. of centers: 1

Reference: Kalapurakal, J.A., et al. (2010). Final Results of a Phase I Dose Escalation Study of Intraoperative Radiation Therapy in Children with Radiation Recurrent Posterior Fossa Tumors. Radiation Oncology, 78(3) Supplement, 19-20

New York, USA | Spine Metastases

Ghaly, M., et al.

Northwell Health

Kypho-Intra Operative Radiation Therapy (IORT) for Localized Spine Metastasis, Phase I/II Study

Scope: Evaluation of response rate of pain control of Kypho-IORT, feasibility, tolerability (side effects) within 90 days post-procedure, determination of clinical factors for vertebral compression fracture.

Evidence: Level 2
No. of patients: 22 planned
No. of centers: 1

Reference: Clinical Trial Identifier: NCT02987153

Learn for yourself about studies and treatment activities undertaken worldwide by your peers.

Changchun, China

Wang, M., et al.

Second Hospital of Jilin University

Single Center Study of Intraoperative Radiotherapy for Middle and Low Rectal Cancer in the Standard of Peritoneal Inversion Rectal Cancer

Scope: Assessment of post-op acute complication and short-term acute efficacy for patients with middle and low rectal cancer treated with IORT after intersphincteric resection.

Evidence: Level 1
No. of patients: 50
No. of centers: 1

Reference: Clinical Trial Identifier: NCT03209336

Chicago, USA

Kalapurakal, J.A., et al.

Northwestern Memorial Hospital

Final Results of a Phase I Dose Escalation Study of Intraoperative Radiation Therapy in Children with Radiation Recurrent Posterior Fossa Tumors

Clinical outcomes of IORT after maximal tumor resection showed no irreversible grade 3 or higher toxicity in patients.

Evidence: Level 2
No. of patients: 11
Median follow-up: 33.0 months
No. of centers: 1

Reference: Kalapurakal, J.A., et al. (2010). Final Results of a Phase I Dose Escalation Study of Intraoperative Radiation Therapy in Children with Radiation Recurrent Posterior Fossa Tumors. Radiation Oncology, 78(3) Supplement, 19-20

Cleveland, USA

Weil, R.J., et al.

Cleveland Clinic

Intraoperative radiotherapy to treat newly diagnosed solitary brain metastasis: initial experience and long-term outcomes

Clinical outcomes for IORT with INTRABEAM® to the cavity during brain metastasis resection show comparable results for local and distant control and long-term survival compared to conventional teatment modalities.

Evidence: Level 2
No. of patients: 23
Median follow-up: 22.0 months
No. of centers: 1

Reference: Weil, R. J., et al. (2015). Intraoperative radiotherapy to treat newly diagnosed solitary brain metastasis: initial experience and long-term outcomes, Journal of Neurosurgery JNS, 122(4), 825-832

Guanzhou, China

Ning, L., et al.

Guangdong Academy of Medical Sciences

Intra-operative Radiotherapy After Breast-conserving Surgery in Treating Women With Ductal Carcinoma in Situ Breast Cancer

Scope: Effectiveness measurement of intraoperatve radiotherapy (IORT) during breast-conserving surgery for low grade ductal carcinoma in situ breast cancer.

Evidence: Level 1
No. of patients: 222
No. of centers: 1

Reference: Clinical Trial Identifier: NCT02389673

London, UK

Vaidya, J., et al.

University College London

Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial

Clinical outcomes of single-dose IORT delivered during breast-conserving surgery show significantly fewer non-breast-cancer deaths compared to EBRT.

Evidence: Level 1
No. of patients: 3451
Median follow-up: 29.0 months
No. of centers: 33

Reference: Vaidya, J. S., et al. (2014). Risk-adapted targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. The Lancet, 383(9917), 603–613.

Also active in London - Vaidya, J., et al., with TARGIT-B comparing IORT Boost with EBRT Boost in early-stage breast cancer, 1790 patients in 35 centers planned (Clinical Trial Identifier: NCT01792726)

Mannheim, Germany

Giordano, F., et al.

University Medical Center Mannheim

A Multicenter Randomized Phase III Trial on INTraoperative RAdiotherapy in Newly Diagnosed GliOblastoma Multiforme (INTRAGO II)

Evidence: Level 1
No. of patients: 314 planned
No. of centers: 20 planned

Reference: Clinical Trial Identifier: NCT02685605

Other Level 1 & 2 studies in Mannheim - INTRAGO I (Brain), a pooled analysis (Brain), TARGIT-E (Breast) and Kypho-IORT (Spine)

Morgantown, USA

Cifarelli, C., et al.

West Virginia University Hospital

Intraoperative radiotherapy (IORT) for surgically resected brain metastases: outcome analysis of an international cooperative study

Evidence: Level 2
No. of patients: 54
Median follow-up: 7.2 months
No. of centers: 3

Reference: Cifarelli, C.P., et al. (2019). Intraoperative radiotherapy (IORT) for surgically resected brain metastases: outcome analysis of an international cooperative study. J Neurooncol 145, 391 397. https://doi:10.1007/s11060-019-03309-6

Also in Morgantown - Vargo, J.A., et al. (2018) investigating the feasibility of dose escalation for IORT vs. SRS during brain metastases resection.

Nantes, France

Le Blanc, M., et al.

Institut De Cancérologie De L'Ouest - Nantes

Medico Economic Study, Randomized, Comparing Intraoperative Radiotherapy With Intrabeam® on Surgical Resection Bed Versus Conventional Surgery + EBRT in Postmenopausal Patients Operated by Conservative Surgery for Low Risk Breast Cancer

Scope: Comparison of IORT with INTRABEAM® versus EBRT, in terms of costs, local-regional survival without recurrence, rate of early and late complications, impact aesthetic outcome and quality of life of patients.

Evidence: Level 1
No. of patients: 246
No. of centers: 9

Reference: Clinical Trial Identifier: NCT03637738

New York, USA

Ghaly, M., et al.

Northwell Health

Kypho-Intra Operative Radiation Therapy (IORT) for Localized Spine Metastasis, Phase I/II Study

Scope: Evaluation of response rate of pain control of Kypho-IORT, feasibility, tolerability (side effects) within 90 days post-procedure, determination of clinical factors for vertebral compression fracture.

Evidence: Level 2
No. of patients: 22 planned
No. of centers: 1

Reference: Clinical Trial Identifier: NCT02987153

Seoul, South Korea

Lee, I.J., et al.

Gangnam Severance Hospital

A Prospective, Phase II Study Investigating Efficacy of Intraoperative Radiation Therapy for Resectable Pancreatic Cancer

Scope: Investigation of IORT efficacy resectable pancreatic adenocarcinoma patients with regards to local recurrence rate after surgical resection with and without IORT.

Evidence: Level 2
No. of patients: 42 planned
No. of centers: 1

Reference: Clinical Trial Identifier: NCT03273374

Stay updated with the latest news on ZEISS INTRABEAM 600

Unable to load form.

Supporting a broad set of oncological indications

ZEISS INTRABEAM 600 enables targeted irradiation of various tumor types

Brain tumors

Brain tumors

Spinal metastases

Spinal metastases

Breast cancer

Breast cancer

Gastrointestinal tumors

Gastrointestinal tumors

Head & neck tumors

Head & neck tumors

Skin cancer

Skin cancer

Peer-to-peer experiences of IORT in the OR using INTRABEAM from ZEISS

Watch clinical live-cases of brain, spine and breast indications performed by clinical experts.

Peer Insights

Clinical experiences with INTRABEAM from ZEISS

INTRAGO-I: Dose escalation study of intraoperative radiotherapy (IORT) in glioblastoma multiforme (GBM)

Read article

Intraoperative Radiation Therapy (IORT): boost during resection of brain metastases

Read article

IORT compared to post-operative stereotactic radiosurgery (SRS) after large brain metastases resection

Read article
See all articles

Downloads

ZEISS INTRABEAM 600
Technical specifications

pages: 24
file size: 1,500 KB

Available services

ZEISS Financial Solutions

The smart way to acquire ZEISS technology.

ZEISS OPTIME

Support when you need it.

Make a sales request

Any questions about buying our products?

Talk to customer care

Do you need assistance or have general questions about your product?

Stay up to date

Subscribe to our newsletter and never miss important updates